On 18 January 2019, the FDA approved the Herceptin®-biosimilar Ontruzant® (trastuzumab-dttb, Samsung BioEpsis), a HER2/neu receptor antagonist, for patients with HER2-overexpressing (HER2+) breast cancer in the adjuvant and metastatic setting, and in metastatic HER2+ gastric cancer patients. Ontruzant® was approved as biosimilar, not as an interchangeable product.
©invincible7 / 123RF Stock Photo
©European Society for Medical Oncology
©American Society for Clinical Oncology (ASCO)
©American Association for Cancer Research
©Chinese Society for Anesthesiology
© European Society for Medical Oncology
©sherryyates / 123RF Stock Photo
Adding ipilimumab (IPI [Yervoy®, Bristol-Myers Squibb]) to nivolumab (NIVO [Opdivo®, Bristol-Myers Squibb]) induction followed by maintenance with single-agent NIVO had a superior objective tumour response rate and progression-free survival (PFS) when compared to NIVO alone in patients with persistent or recurrent epithelial ovarian cancer.
The Enhanced Recovery after Surgery (ERAS) Society recently published Part 1 of the Society's 3-part caesarean delivery guidelines, focussed on pre-operative care for women undergoing scheduled and unscheduled caesarean delivery, in the American Journal of Obstetrics & Gynecology. Caesarean delivery is the most common surgical procedure in the modern world.
© Copyright – MediPaper Medical Communications – Medical Communications & Health News
MediPR | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | Medical Writer Jobs | MediNews.asia | Anaesthesiology.asia